Pancreatic Cancer Research

ResearcherInstitute of Science TokyoActive in the last 2 years

Daisuke Ban

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0868-8519; OpenAlex author ID A5011945679. Sources: OpenAlex.

Their work

Papers
24 (first author 6, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
106
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: none · 2024: 3 papers · 2025: 4 papers · 2026: 6 papers

Papers 24

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models. Co-author DOI 10.1016/j.ebiom.2026.106137↗
  4. Percutaneous abdominal lavage cytology screening reduces non-therapeutic laparotomy in patients with pancreatic cancer considered for curative-intent resection… First author DOI 10.1016/j.surg.2026.110444↗
  5. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  6. CD73 is associated with glycolysis related metabolic programs and CD8+ T cell suppression in pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fimmu.2026.1873813↗
  7. Neoadjuvant gemcitabine and S-1 in pancreatic ductal adenocarcinoma: Effects on nutritional status and pancreaticoduodenectomy outcomes. Co-author DOI 10.1016/j.surg.2024.109026↗
  8. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Co-author DOI 10.1016/j.surg.2025.109783↗
  9. PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-24-1095↗
  10. Late-Onset Para-Aortic Lymph Node Recurrence 11 Years after Resection of Pancreatic Cancer: Histological Reassessment Revealed Neuroendocrine Differentiation A… Last author DOI 10.70352/scrj.cr.25-0374↗
  11. Oligo-like liver metastasis: A novel prognostic indicator to improve survival in pancreatic cancer. First author DOI 10.1002/ags3.12753↗
  12. Safety and feasibility of percutaneous abdominal lavage cytology screening (PACS) prior to surgical resection for pancreatic cancer. Co-author DOI 10.1007/s00261-024-04510-6↗
  13. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  14. Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Co-author DOI 10.1245/s10434-022-11950-1↗
  15. ASO Author Reflections: Prognostic Impact of Radiological Splenic Artery Involvement in Pancreatic Ductal Adenocarcinoma of the Body and Tail. Co-author DOI 10.1245/s10434-022-11957-8↗
  16. Extraordinary first jejunal arterial variation associated with annular pancreas undergoing pancreaticoduodenectomy for pancreatic cancer: a case report. First author DOI 10.1007/s00276-020-02671-9↗
  17. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Co-author DOI 10.1038/s41598-021-89530-8↗
  18. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. First author DOI 10.1371/journal.pone.0249885↗
  19. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0252917↗
  20. Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting fo… First author DOI 10.1186/s40792-020-01082-7↗
  21. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Co-author DOI 10.1002/ijc.32072↗
  22. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. First author DOI 10.1002/jhbp.366↗
  23. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis. Co-author DOI 10.1371/journal.pone.0146564↗
  24. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Co-author DOI 10.1053/j.gastro.2012.03.054↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Nara · 6 shared papers, 2022–2026 · strength 1.32
  2. Minoru Esaki · 6 shared papers, 2022–2026 · strength 1.32
  3. Shinji Tanaka · 10 shared papers, 2012–2026 · strength 1.16
  4. Takeshi Takamoto · 5 shared papers, 2022–2025 · strength 1.02
  5. Minoru Tanabe · 9 shared papers, 2016–2025 · strength 0.99
  6. Atsushi Oba · 5 shared papers, 2016–2026 · strength 0.86
  7. Yosuke Inoue · 4 shared papers, 2025–2026 · strength 0.81
  8. Shunsuke Sugawara · 4 shared papers, 2022–2026 · strength 0.78
  9. Hiroaki Ono · 6 shared papers, 2019–2025 · strength 0.74
  10. Nobuyoshi Hiraoka · 3 shared papers, 2022–2026 · strength 0.60
  11. Michiaki Unno · 3 shared papers, 2024–2026 · strength 0.56
  12. Eriko Katsuta · 2 shared papers, 2025–2026 · strength 0.55
  13. Kosuke Ogawa · 5 shared papers, 2019–2021 · strength 0.55
  14. Kazuaki Shimada · 3 shared papers, 2022–2024 · strength 0.54
  15. Ryosuke Umino · 2 shared papers, 2024–2026 · strength 0.48
  16. Aya Maekawa · 3 shared papers, 2020–2025 · strength 0.43
  17. Kentaro Umemura · 2 shared papers, 2025–2026 · strength 0.42
  18. Yosuke Igarashi · 2 shared papers, 2025–2026 · strength 0.42
  19. Yoshiaki Tanji · 2 shared papers, 2025–2026 · strength 0.42
  20. Shuichi Watanabe · 4 shared papers, 2019–2021 · strength 0.42
  21. So Yamaki · 2 shared papers, 2026 · strength 0.41
  22. Sohei Satoi · 2 shared papers, 2026 · strength 0.41
  23. Teiichi Sugiura · 2 shared papers, 2026 · strength 0.41
  24. Kenjiro Okada · 2 shared papers, 2026 · strength 0.41
  25. Ryuta Shintakuya · 2 shared papers, 2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.